Pharmaceutical Care Contributes to the Advanced Management of Patients Receiving Immune Checkpoint Inhibitors.
Pharmaceutical Care Contributes to the Advanced Management of Patients Receiving Immune Checkpoint Inhibitors.
复制标题
药学服务有助于对接受免疫检查点抑制剂的患者进行高级管理。
DOI：
--
复制
发表时间：
2020
影响因子：
2
通讯作者：
M. Sugawara
中科院分区：
文献类型：
--
作者：
Y. Saito;Kazuki Uchiyama;Tatsuhiko Sakamoto;Kojiro Yamazaki;Kosei Kubota;Y. Takekuma;Y. Komatsu;M. Sugawara
我们之前曾报道，肿瘤学药学专家的连续药学护理有助于提高门诊化疗的质量。然而，尽管越来越多的患者接受免疫检查点抑制剂(ICIS)治疗，而且免疫相关不良事件的概况与细胞毒药物的不良反应截然不同，但仍有一些关于免疫检查点抑制剂(ICIS)治疗期间此类护理的报道。我们回顾评估了持续药学服务在ICI门诊治疗中的效果，特别是在提供药物建议的阶段。评估药物干预的采用率、有效性和周期，如处方问题和药物建议。总共评估了3597次ICI给药(366名患者)。我们进行了2625次面对面的用药咨询。共有282个处方问题和147个药物建议进行了调查。约70%的问题是关于实验室检查的顺序，86.5%的问题被采纳。药品推荐依次为用药推荐(81.1%)、检查推荐(10.8%)和专家咨询推荐(8.1%)。用药建议采用率为96.0%，70%的用药建议缓解症状。最后，在ICI治疗开始后的前3个月，药物建议的供应率明显更高。我们发现，药学服务有助于提高门诊ICI治疗的质量，最重要的是在ICI治疗开始后3个月内进行面对面的药物咨询。
We previously reported that successive pharmaceutical care by oncology pharmacy specialists contributes to quality outpatient chemotherapy. However, there are a few reports regarding such care during immune checkpoint inhibitors (ICIs) treatment, despite increasing patients being treated with ICIs and the profile of immune-related adverse events being quite different from that of the adverse effects of cytotoxic agents. We retrospectively evaluated the effectiveness of continuous pharmaceutical care in outpatient ICI treatment, focusing especially on the period of providing pharmaceutical recommendations. The adoption rate, efficacy, and period of pharmaceutical interventions, such as prescription questions and pharmaceutical recommendations, were evaluated. A total of 3597 ICI administrations (366 patients) were evaluated. We performed 2625 face-to-face medication counseling. A total of 282 prescription questions and 147 pharmaceutical recommendations were conducted. Approximately 70% of the questions were regarding ordering of laboratory examination, and 86.5% of these questions were adopted. Pharmaceutical recommendations were categorized into medication recommendations (81.1%), examination recommendations (10.8%), and recommendation of expert consultation (8.1%). The adoption rate of pharmaceutical recommendations was 96.0, and 70% of the medication recommendations attenuated the symptoms. Finally, the provision rate of pharmaceutical recommendations was significantly higher in the first 3 months after ICI treatment initiation. We found that pharmaceutical care contributes to an improved quality of outpatient ICI treatment, and face-to-face pharmaceutical counseling up to 3 months after ICI treatment initiation is the most important.
DOI：
10.1016/s1470-2045(14)70189-5
发表时间：
2014-06
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Kwon ED;Drake CG;Scher HI;Fizazi K;Bossi A;van den Eertwegh AJ;Krainer M;Houede N;Santos R;Mahammedi H;Ng S;Maio M;Franke FA;Sundar S;Agarwal N;Bergman AM;Ciuleanu TE;Korbenfeld E;Sengeløv L;Hansen S;Logothetis C;Beer TM;McHenry MB;Gagnier P;Liu D;Gerritsen WR;CA184-043 Investigators
通讯作者：
CA184-043 Investigators